Viridian Therapeutics, INC.\De (VRDN) — 10-Q Filings

10-Q Filings (6)

• Viridian Narrows Q3 Loss to $34.6M on Soaring License Revenue — Nov 5, 2025 Risk: high
  Viridian Therapeutics, Inc. reported a net loss of $34.599 million for the three months ended September 30, 2025, a significant improvement from the $76.689 mil
• Viridian's Q2 Net Loss Widens to $60.2M Amid R&D Surge — Aug 6, 2025 Risk: high
  Viridian Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The net loss for the
• Viridian Therapeutics Files Q1 2025 10-Q — May 6, 2025 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial
• Viridian Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Miragen Therapeutics, Inc. and Signal Geneti
• Viridian Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Viridian Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Signal Genetics, Inc. and Miragen Therapeutics, I
• Viridian Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Viridian Therapeutics, Inc.\DE (VRDN) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Viridian Therapeutics, Inc. filed a 10-Q report for the perio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX